Pre-made Golimumab benchmark antibody ( Whole mAb, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Golimumab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Golimumab is a human monoclonal antibody which is used as an immunosuppressive medication and sold under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-249-1mg	1mg	3090
GMP-Bios-ab-249-10mg	10mg	Inquiry
GMP-Bios-ab-249-100mg	100mg	Inquiry
GMP-Bios-ab-249-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Golimumab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody
INN Name	Golimumab
Target	TNF
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	5yoy:RO:IF:QN:GD:HE:PM
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2004
Year Recommended	2005
Companies	Centocor;Centocor Ortho Biotech;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;Medarex
Conditions Approved	Ankylosing spondylitis;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis
Conditions Active	Hearing disorders;Type 1 diabetes mellitus
Conditions Discontinued	Asthma;Cardiovascular disorders;Sarcoidosis;Uveitis
Development Tech	Medarex UltiMAb Mouse